From: Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy
Variable | Percentage (%) |
---|---|
Patient (n) | 50 |
Gleason score (n, %) | |
6 | 3 (6%) |
7 | 15 (30%) |
8 | 25 (50%) |
9 | 7 (14%) |
Site of metastasis (n, %) | |
Bone | 41 (82%) |
Lymph node | 6 (12%) |
Organ | 3 (6%) |
Gleason scores (median, range) | 8 (range 6–9) |
Pre-therapeutic PSA (ng/ml) (median, range) | 50 (8–1201) |
Nadir PSA (ng/ml) (median) | 1.1 (0.02–50) |
Time to nadir PSA (month) (mean ± SD, range) | 3.85 ± 1.6 (1–7) |
Cores involved (mean ± SD, range) | 5.39 ± 3.11 (1–11) |
Percentage of cores involved (mean ± SD, range) | 67.12 ± 27.14 (4–100) |
PSA at last follow-up (ng/ml) (median, range) | 1.95 (0.02–85) |